PMID- 36008432
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20221101
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Aug 25
TI  - Metformin administration is associated with enhanced response to transarterial 
      chemoembolization for hepatocellular carcinoma in type 2 diabetes patients.
PG  - 14482
LID - 10.1038/s41598-022-18341-2 [doi]
LID - 14482
AB  - Transarterial chemoembolization (TACE) is often used as a locoregional therapy 
      for early hepatocellular carcinoma (HCC) when local ablation or resection are not 
      feasible, but incomplete response and recurrence are commonly observed. In this 
      study, we sought to determine the association between metformin administration 
      and TACE outcomes for single nodular HCC in patients with type 2 diabetes 
      mellitus (T2DM). The retrospective cohort analysis included 164 T2DM patients 
      with single nodular HCC who underwent TACE as an initial treatment, and 91 were 
      exposed to metformin before and after TACE. Propensity score (PS) matching was 
      used to balance covariates. Logistic regression analysis was used to determine 
      the predictors of tumor response after TACE, and Cox regression analysis assessed 
      independent predictors of local tumor recurrence (LTR) in patients with complete 
      response after TACE. Metformin use was associated with significantly higher 
      objective response rate (ORR) in the overall and PS-matched cohort (79.1% vs. 
      60.3 and 78.7% vs. 57.5%; p = 0.008 and p = 0.029, respectively). Logistic 
      regression analysis showed that metformin use was an independent predictor of ORR 
      in all and PS-matched patients (odds ratio = 2.65 and 3.06; p = 0.016 and 0.034, 
      respectively). Cox regression analysis showed metformin administration was an 
      independent predictor for lower LTR in all and PS-matched patients (hazard 
      ratio = 0.28 and 0.27; p = 0.001 and 0.007, respectively). Metformin 
      administration is associated with better initial response and lower local 
      recurrence after TACE for single nodular HCC in T2DM.
CI  - (c) 2022. The Author(s).
FAU - Jung, Woo Jin
AU  - Jung WJ
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Jang, Sangmi
AU  - Jang S
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Choi, Won Joon
AU  - Choi WJ
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Park, Jaewon
AU  - Park J
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Choi, Gwang Hyeon
AU  - Choi GH
AUID- ORCID: 0000-0002-8795-8427
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Jang, Eun Sun
AU  - Jang ES
AUID- ORCID: 0000-0003-4274-2582
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
FAU - Jeong, Sook-Hyang
AU  - Jeong SH
AUID- ORCID: 0000-0002-4916-7990
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
AD  - Department of Internal Medicine, College of Medicine, Seoul National University, 
      Seoul, Republic of Korea.
FAU - Choi, Won Seok
AU  - Choi WS
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
AD  - Department of Radiology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Jae Hwan
AU  - Lee JH
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
AD  - Department of Radiology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Yoon, Chang Jin
AU  - Yoon CJ
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea.
AD  - Department of Radiology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Jin-Wook
AU  - Kim JW
AUID- ORCID: 0000-0003-0934-3344
AD  - Departments of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Gumi-dong 300, Seongnam, 
      Kyonggi-Do, 463-802, Republic of Korea. kimjinw@snu.ac.kr.
AD  - Department of Internal Medicine, College of Medicine, Seoul National University, 
      Seoul, Republic of Korea. kimjinw@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220825
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Carcinoma, Hepatocellular/pathology/therapy
MH  - *Chemoembolization, Therapeutic
MH  - *Diabetes Mellitus, Type 2/complications/therapy
MH  - Humans
MH  - *Liver Neoplasms/pathology/therapy
MH  - *Metformin/therapeutic use
MH  - Neoplasm Recurrence, Local/therapy
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC9411109
COIS- The authors declare no competing interests.
EDAT- 2022/08/26 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/08/25
CRDT- 2022/08/25 23:19
PHST- 2021/12/15 00:00 [received]
PHST- 2022/08/09 00:00 [accepted]
PHST- 2022/08/25 23:19 [entrez]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 10.1038/s41598-022-18341-2 [pii]
AID - 18341 [pii]
AID - 10.1038/s41598-022-18341-2 [doi]
PST - epublish
SO  - Sci Rep. 2022 Aug 25;12(1):14482. doi: 10.1038/s41598-022-18341-2.